Financial Data and Key Metrics Changes - In 2025, the company achieved full-year revenue of over $35 million, growing approximately 60% year-over-year from less than $23 million in 2024 [5][27] - Gross margins improved to greater than 50% by the end of 2025, up from around 25% the previous year [5][27] - The net loss for 2025 was $69.1 million, a decrease from a net loss of $78.6 million in 2024 [27][28] Business Line Data and Key Metrics Changes - U.S. revenue for Q4 2025 was $12.1 million, while revenue outside the U.S. was $2.2 million [24] - The number of Eversense users in the U.S. more than doubled from 2024 to 2025, with new patient starts growing 103% [5][20] - The number of providers actively prescribing Eversense grew more than 80% year-over-year [21] Market Data and Key Metrics Changes - The company expects Europe to contribute about 20% of total revenue in 2026 following the launch of Eversense 365 [41] - The company anticipates full-year 2026 global net revenue to be approximately $58 million-$62 million, representing year-over-year growth of 65%-76% [28][29] Company Strategy and Development Direction - The company transitioned all commercial activities from Ascensia Diabetes Care back to Senseonics, enhancing operational efficiency and control [7][8] - The integration with Sequr Med Tech's twiist Automated Insulin Delivery System is a significant milestone, expected to simplify life for patients requiring insulin [10] - The company plans to launch Eversense 365 in several European markets in Q2 2026, with a dedicated sales force [12][106] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, driven by strategic decisions made in 2025 and the integration of commercial operations [6][32] - The company noted that Q4 is typically the strongest quarter due to insurance deductibles being met, and expects similar trends in 2026 [11][29] - Management highlighted the importance of patient retention and the effectiveness of direct-to-consumer marketing strategies [17][18] Other Important Information - The company raised capital from institutional investors and executed a reverse stock split, beginning trading on Nasdaq [10] - Research and development expenses decreased in 2025 due to the completion of clinical trials for Eversense 365 [25][28] Q&A Session Summary Question: Trends in new patient starts at the beginning of the year - Management noted that new patient growth continues as expected, with January typically being the softest month due to patient resets [37] Question: Contribution of Europe and twiist to revenue guidance - Management indicated that Europe is expected to contribute about 20% of revenue in 2026, with unique economics for each company involved in the twiist integration [39][41] Question: Seamlessness of the commercial transition from Ascensia - Management confirmed that the transition was straightforward in the U.S., with nearly 100% of employees transitioning smoothly [44] Question: Growth of the prescriber base and patient starts - Management expressed optimism about the potential for accelerated growth in the prescriber base and new patient starts, supported by increased awareness and DTC investments [50] Question: Challenges in expanding the EonCare inserter network - Management stated that the expansion is primarily dependent on volume and demand, with no significant barriers to increasing the number of inserters [81] Question: Timeline for the rollout in Europe - Management expects the transition to occur in Q2 2026, with some tenders potentially extending into early fall [105][106]

Financial Performance - Tandem Diabetes Care reported quarterly losses of 1 cent per share, outperforming the analyst consensus estimate of losses of 8 cents per share [1] - The company achieved quarterly sales of $290.400 million, exceeding the analyst consensus estimate of $277.029 million [1] Future Outlook - For FY2026, Tandem Diabetes Care projects sales between $1.065 billion and $1.085 billion, compared to market estimates of $1.103 billion [1] - The CEO highlighted that 2025 was a significant year with over $1 billion in worldwide sales and record gross margins, indicating a strong foundation for future growth [2] Market Reaction - Following the earnings announcement, Tandem Diabetes Care shares increased by 36%, reaching a trading price of $25.19 [2]

Core Insights - CVS Health Foundation has granted $2.6 million to the American Diabetes Association (ADA) to expand its maternal health initiative in New York City, building on 18 months of successful outcomes in improving gestational diabetes screening and care coordination [1][2] Group 1: Program Expansion - The initiative will expand to two additional communities in New York City, aiming to support more families during the prenatal and postpartum journey [6] - The program will enhance electronic medical records (EMR) dashboards to streamline referrals among healthcare providers, ensuring seamless care transitions [6] - Increased access to advanced diabetes technology, including continuous glucose monitoring (CGM), will be provided, along with medically tailored meals to address food insecurity [6] Group 2: Health Statistics and Impact - At Wyckoff Heights Medical Center, over 20% of patients have diabetes, with 56% having an A1C above 9%, indicating poor blood sugar control [3] - Gestational diabetes mellitus (GDM) affects up to 9% of pregnancies nationwide, with rates in New York City rising from 6% in 2016 to 8.3% in 2021 [8] - In Bushwick, Brooklyn, 19% of adults have diabetes, and avoidable hospitalizations are 70% higher than the city average [8] Group 3: Patient Support and Education - The program provides multilingual education for patients and community health workers to support healthy pregnancies and postpartum care [7] - Patients like C.H., who was diagnosed with gestational diabetes, have benefited from nutritional workshops and support from community health workers, leading to improved confidence in managing their health [9][10] Group 4: Organizational Background - The CVS Health Foundation focuses on addressing health challenges through collaboration with nonprofit organizations, with a commitment to enhancing health outcomes in various areas, including maternal health and chronic conditions like diabetes [10] - The American Diabetes Association (ADA) is a leading health organization dedicated to fighting diabetes and supporting individuals affected by the condition, celebrating 85 years of advocacy and program development [11]

Core Insights - embecta Corp. has expanded its partnership with Direct Relief to enhance access to diabetes care for underserved communities in the U.S. and globally [1][2][3] Company Overview - embecta was spun off from Becton, Dickinson and Company in 2022, acquiring BD-branded pen needles and insulin syringes [2] - The company has updated its packaging in North America from the BD brand to the embecta brand in 2025 [2] - Since becoming independent, embecta has focused on empowering individuals with diabetes and ensuring access to necessary supplies [3] Partnership Details - embecta has donated approximately 15 million units of pen needles and insulin syringes to Direct Relief, marking its largest humanitarian partnership since independence [2] - The partnership aims to provide essential diabetes management supplies to uninsured and low-income patients through Direct Relief's Safety Net Support Program [4][5] - Direct Relief collaborates with over 1,600 community health centers and clinics, serving more than 36 million patients, including a significant portion of the uninsured population in the U.S. [4] Global Impact - The partnership supports Direct Relief's Life for a Child program, which provides diabetes care to over 53,000 children and young people in 45 countries [6] - embecta's donations also support diabetes care in crisis-affected regions, including a recent donation of 2.7 million insulin needles and syringes for a campaign in Sudan [8][7] Educational Initiatives - embecta supports diabetes education camps through Direct Relief, providing essential supplies to help children and young adults learn diabetes management skills [10] Emergency Response - The partnership includes emergency response capabilities, with a recent grant of $25,000 from embecta to support disaster relief efforts in Texas [11] Industry Context - Over 537 million people globally live with diabetes, with projections reaching 783 million by 2045; in the U.S., approximately 38 million individuals are affected [12] - Access to affordable diabetes care remains a critical challenge, particularly for uninsured and underinsured populations [12]